Previous 10 | Next 10 |
Natera Announces New Prospera™ Data at the ATC 2021 Virtual Connect Conference PR Newswire AUSTIN, Texas , June 4, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it wi...
Natera Responds to Meritless Lawsuit and Files False Advertising Claim Against Guardant for Misleading Oncologists PR Newswire AUSTIN, Texas , May 28, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testi...
New Signatera™ Data in Multiple Myeloma, Colorectal Cancer and Ovarian Cancer Highlights Clinical Utility of MRD in Real-World Settings PR Newswire AUSTIN, Texas , May 26, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leade...
Natera to Present Clinical Data from Largest Prospective MRD-Guided Trial in Colorectal Cancer at the 2021 ASCO Annual Meeting Initial analysis of 400 patients from CIRCULATE-Japan study showcases Signatera's market-leading performance with over 95% pre-surgical detection and 92...
Natera, Inc. (NTRA) Q1 2021 Earnings Conference Call May 06, 2021 4:30 PM ET Company Participants Michael Brophy – Chief Financial Officer Steve Chapman – Chief Executive Officer Solomon Moshkevich – General Manager of Oncology Conference Call Participants Tejas Savant ...
The following slide deck was published by Natera, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Natera, Inc. 2021 Q1 - Results - Earnings Call Presentation
Natera (NTRA): Q1 GAAP EPS of -$0.74 beats by $0.28.Revenue of $152.3M (+62.0% Y/Y) beats by $37.88M.Press Release For further details see: Natera EPS beats by $0.28, beats on revenue
Natera Reports First Quarter 2021 Financial Results PR Newswire AUSTIN, Texas , May 6, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the first quarter ended ...
Natera to Present New Colorectal Cancer and Multiple Myeloma Data at the 2021 Annual ASCO Meeting ASCO presentations come on the heels of new Signatera™ data in ovarian cancer presented at AACR PR Newswire AUSTIN, Texas , May 3, 2021 /PRNewswire/ -...
Natera Announces First Quarter 2021 Earnings Conference Call PR Newswire AUSTIN, Texas , April 29, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its...
News, Short Squeeze, Breakout and More Instantly...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2024, after the market close on Aug. 8, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET...
Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncolog...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...